Literature DB >> 7541812

Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin.

H Mizutani1, H Taniguchi, T Sakakura, M Shimizu.   

Abstract

Nodular scleroderma is a rare variant of the disease, whose pathogenesis is uncertain. Tenascin is a recently cloned extracellular matrix protein which is thought to be a marker for tissue remodelling. To further investigate the pathogenesis of nodular scleroderma, we have followed up a case of this disease and studied tenascin expression in the nodular lesions and surrounding progressive systemic sclerosis skin. Previously, we demonstrated a long-lasting intermediate level of dermal tenascin expression in progressive systemic sclerosis; morphea and hypertrophic scar lesions showed strong but short-lived tenascin expression. In our current patient, high levels of tenascin were found in the nodules, which rapidly resolved. Thus, the time course of the clinical and histopathological findings together with the tenascin expression were more suggestive of hypertrophic scar than progressive systemic sclerosis. These findings imply that nodular scleroderma has a supplementary pathogenesis, such as itching, in addition to the proceeding systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541812     DOI: 10.1111/j.1346-8138.1995.tb03384.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

1.  Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3.

Authors:  Monique Brissett; Kristen L Veraldi; Joseph M Pilewski; Thomas A Medsger; Carol A Feghali-Bostwick
Journal:  Arthritis Rheum       Date:  2012-01

2.  Keloids in scleroderma-keloidal scleroderma: a unique entity.

Authors:  Sumit Sen; Tanusree Biswas; Gautam Banerje; Saugato Biswas
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

3.  Keloidal scleroderma.

Authors:  Mittermayer Santiago; Dálvaro Oliveira de Castro; Cíntia Andrade Costa; Edgard Souza Passos; Ariene Paixão
Journal:  Clin Rheumatol       Date:  2003-12-18       Impact factor: 2.980

4.  Keloidal Scleroderma: Case Report and Review.

Authors:  Sama Kassira; Tarannum Jaleel; Peter Pavlidakey; Naveed Sami
Journal:  Case Rep Dermatol Med       Date:  2015-11-30

5.  Scleroderma with Nodular Scleroderma.

Authors:  Chutika Srisuttiyakorn; Kobkul Aunhachoke
Journal:  Case Rep Dermatol       Date:  2016-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.